Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
Oragenics (NYSE American: OGEN), a biotech company focused on intranasal therapeutics for brain-related conditions, announces its participation in two major industry events in June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Details
News Market Reaction – OGEN
The recorded move for OGEN in the trading session of this news was +4.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania.
These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.
2025 BIO International Convention
- Dates: June 16–19, 2025
- Location: Boston Convention & Exhibition Center, Boston, MA
- Presentation Date & Time: June 19, 2025, from 11:30 AM – 11:45 AM ET
- Registration: https://www.bio.org/events/bio-international-convention/registration
42nd Annual National Neurotrauma Society (NNS) Symposium
- Dates: June 15–18, 2025
- Location: Philadelphia Marriott Downtown, Philadelphia, PA
- Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care
About Oragenics, Inc.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company’s intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit www.oragenics.com.
Investor Contact:
Rich Cockrell
CG Capital
866.889.1972
ogen@cg.capital
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.